{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:53:53Z","timestamp":1782993233923,"version":"3.54.5"},"reference-count":26,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2013,3,19]],"date-time":"2013-03-19T00:00:00Z","timestamp":1363651200000},"content-version":"vor","delay-in-days":2787,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2005,8]]},"abstract":"<jats:p>This study assessed the effect of the proton pump inhibitor omeprazole on the bioavailability of the extended\u2010release formulations of oxybutynin and tolterodine. Forty\u2010four healthy volunteers received each of 4 treatments in a 4\u2010period crossover design. The treatments consisted of osmotically controlled extended\u2010release oxybutynin chloride tablets at 10 mg\/d or extended\u2010release tolterodine tartrate capules at 4 mg\/d, with and without preceding treatment with 20 mg omeprazole daily for 4 days. Blood samples collected predose and at scheduled time points for 36 hours postdose were analyzed for oxybutynin and its active metabolite, N\u2010desethyloxybutynin, or tolterodine and its active 5\u2010hydroxymethyl metabolite, as appropriate. The AUC<jats:sub>\u221e<\/jats:sub> ratios for oxybutynin and its metabolite with and without prior omeprazole fell within the 80% to 125% range (accepted as the criterion for bioequivalence), as did those for tolterodine and its active moiety. The peak concentration ratios for oxybutynin and metabolite also conformed to this range; those for tolterodine did not. Increasing gastric pH with omeprazole does not substantially alter the pharmacokinetic properties of extended\u2010release oxybutynin but may alter those of extended\u2010release tolterodine.<\/jats:p>","DOI":"10.1177\/0091270005278055","type":"journal-article","created":{"date-parts":[[2005,7,18]],"date-time":"2005-07-18T21:03:28Z","timestamp":1121720608000},"page":"961-968","source":"Crossref","is-referenced-by-count":9,"title":["Effect of the Proton Pump Inhibitor Omeprazole on the Pharmacokinetics of Extended\u2010Release Formulations of Oxybutynin and Tolterodine"],"prefix":"10.1002","volume":"45","author":[{"given":"Roger","family":"Dmochowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayatri","family":"Sathyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"MacDiarmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Gidwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneel","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,19]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200118040-00005"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00558247"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001929970003"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2680.2001.00231.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/009127009903900313"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140030-00006"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.01463.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)68810-6"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)01113-4"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600770908"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1996.tb03936.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1997.tb00027.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050096"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122010113"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140020-00005"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00865.x"},{"key":"e_1_2_6_18_2","unstructured":"DmochowskiR.The effect of pH on drug release from extended\u2010release formulations of oxybutynin and tolterodine. In: 2nd International Consultation on Incontinence of the World Health Organization;July 2001; Paris."},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443140-00008"},{"key":"e_1_2_6_20_2","unstructured":"ZhouM FordL NiggebruggeA.Applications of automated HTLC\u2010MS\/MS in bioanalytical laboratories. In: International Symposium on Pharmaceutical and Biomedical Analysis;September 2003; Orlando Fla."},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)89661-6"},{"key":"e_1_2_6_22_2","first-page":"289","article-title":"Tolterodine a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes","volume":"26","author":"Postlind H","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90104-7"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-081X(199903)20:2<91::AID-BDD162>3.0.CO;2-Y"},{"key":"e_1_2_6_25_2","first-page":"287","article-title":"Sample size determination: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43","volume":"30","author":"Diletti E","year":"1992","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"e_1_2_6_26_2","unstructured":"US Food and Drug Administration.Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products: General Considerations. Accessed August 1 2003 fromwww.fda.govcderguidanceindex.htm."},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/009127000004001004"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270005278055","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270005278055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:20:56Z","timestamp":1697156456000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270005278055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["10.1177\/0091270005278055"],"URL":"https:\/\/doi.org\/10.1177\/0091270005278055","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}